DOC.03 // FAQ
Frequently Asked Questions
Procedural and regulatory questions about the bremelanotide (PT-141) telehealth pathway, answered with citations.
Can bremelanotide (PT-141) be prescribed through telehealth?
Yes, in most U.S. states, when a state-licensed clinician conducts a synchronous video visit, makes a clinical diagnosis of acquired, generalized HSDD in a premenopausal woman, documents informed consent, and transmits the prescription to a licensed dispensing pharmacy [12][18]. Because bremelanotide is not a controlled substance under the federal Controlled Substances Act, the Ryan Haight in-person evaluation requirement does not apply [12][19]. State medical-board rules govern the establishment of the provider-patient relationship, and most states accept synchronous audiovisual encounters as sufficient for non-controlled prescribing.
Does the Ryan Haight Act require an in-person visit before bremelanotide can be prescribed online?
No. The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 requires at least one in-person medical evaluation before a controlled substance can be prescribed via the internet. Its in-person rule applies only to Schedule II–V drugs under the federal Controlled Substances Act. Bremelanotide is not a controlled substance, so the Ryan Haight in-person requirement does not apply [12][19]. The relevant rules for bremelanotide are general standard-of-care telemedicine rules set by state medical boards — not federal DEA telehealth flexibilities.
What happens during a telehealth visit for HSDD and bremelanotide evaluation?
Before the visit, the patient typically completes a secure intake form covering medical history, current medications, blood-pressure history, and validated HSDD screening (DSDS, FSFI desire domain, FSDS-DAO Item 13). During the synchronous video visit, the clinician reviews the screeners, applies the biopsychosocial framework to confirm acquired, generalized HSDD, screens for cardiovascular contraindications, documents informed consent specific to bremelanotide, and — if appropriate — transmits an electronic prescription to a licensed dispensing pharmacy [12][15][18]. The visit is largely history-driven, which is why the bremelanotide evaluation suits a remote modality [15].
What kind of clinician evaluates and prescribes bremelanotide remotely?
Most commonly OB/GYNs and sexual medicine specialists, with family medicine and internal medicine clinicians also represented [12][18]. The 2025 ACOG Committee Statement No. 20 frames telehealth as ethically appropriate within OB/GYN practice when standard-of-care requirements are met [18]. Specialist credentials may include affiliation with the International Society for the Study of Women's Sexual Health (ISSWSH) or the International Society for Sexual Medicine (ISSM). A legitimate platform should be able to identify the prescribing clinician by name and license.
Is the same bremelanotide product dispensed through telehealth as in-person?
When the prescription is for the FDA-approved product, the answer is yes: the single-dose 1.75 mg subcutaneous autoinjector is the same regardless of whether the prescription originated in-person or by telehealth [06][10]. A separate category is compounded bremelanotide preparations, made by 503A or 503B pharmacies; these are not FDA-evaluated for identity, purity, or stability, and the FDA has placed PT-141 in its compounding-category framework, restricting eligibility for compounding under certain conditions [19]. The clinical and pharmacokinetic data summarized on this site applies to the FDA-approved product.
Do I need to provide a blood pressure reading during a telehealth visit for PT-141?
Most clinicians want one. The label contraindicates bremelanotide in uncontrolled hypertension and known cardiovascular disease, on the basis of the small, transient post-dose systolic blood-pressure rise of 2.4–3.2 mmHg observed in an ambulatory monitoring study of 397 women [05][06][12]. In a remote encounter, the BP reading is typically obtained by patient self-report from an at-home cuff or from a recent in-person measurement. Some platforms decline to prescribe without a documented BP reading.
How is the diagnosis of HSDD made over video — what questions will the clinician ask?
The clinician applies the biopsychosocial framework documented by the ICSM guidelines and the sexual-medicine literature [12][15]. Three validated instruments are standard: the Decreased Sexual Desire Screener (a brief 5-item screener), the FSFI desire domain (a multi-item scale capturing desire over the prior four weeks), and FSDS-DAO Item 13 (a single-item measure of distress about low desire). The clinician asks about onset (acquired vs. lifelong), context (generalized vs. situational), distress, and the medical, psychiatric, medication-related, or relational factors that might explain the low desire [12]. The FDA indication is the acquired, generalized presentation in premenopausal women [06].
Which states allow telehealth prescribing of bremelanotide?
Most do for non-controlled drugs, but specifics vary. State medical boards set the rules for establishing a provider-patient relationship by telemedicine, the informed-consent requirements, and the follow-up obligations [12][18]. The prescribing clinician must hold an active license in the state where the patient is physically located at the time of the encounter, and the dispensing pharmacy must be licensed for that state [12]. Interstate compacts such as the Interstate Medical Licensure Compact streamline multi-state credentialing. A platform that operates nationally typically maintains a clinician panel credentialed across multiple states.
How is bremelanotide shipped after a telehealth prescription?
The licensed dispensing pharmacy ships the single-dose 1.75 mg subcutaneous autoinjector to the patient. The autoinjector format is the FDA-approved presentation [10]. The drug does not require strict cold-chain handling at the patient level. Shipping logistics and timing depend on the pharmacy and the platform. The pharmacy should be a state-licensed dispensing pharmacy operating in the state where the patient is receiving the shipment; the FDA-approved product is the dispensed product unless the prescription is explicitly for a compounded preparation, which is a separate regulatory category [19].
What follow-up will I have after a telehealth bremelanotide prescription?
The sexual-medicine telehealth literature describes follow-up at four to eight weeks by video visit or secure messaging, with reassessment of efficacy (re-administered FSFI-D and FSDS-DAO Item 13), tolerability (nausea, flushing, headache, injection-site reactions, hyperpigmentation surveillance), and adherence to the labeled use limits [15][18]. Continuity of care is the patient's right; ACOG Committee Statement No. 20 (2025) explicitly emphasizes that telehealth providers retain the same continuity-of-care obligations as in-person clinicians [18].
How is the FDA-approved bremelanotide product different from 'research peptide' PT-141 sold online?
The FDA-approved product is the 1.75 mg subcutaneous autoinjector evaluated and approved by the FDA in 2019, manufactured under federal oversight, dispensed by licensed pharmacies on a valid prescription [06][10]. 'Research peptide' PT-141 vials sold by unregulated online vendors are not FDA-approved products. They have not been evaluated for identity, purity, stability, sterility, or potency. Compounded preparations from 503A or 503B pharmacies are a third, separate regulatory category; the FDA has placed PT-141 in its compounding-category framework with restrictions on eligibility [19]. The clinical, pharmacokinetic, and safety data summarized on this site applies to the FDA-approved product.
What are the side effects I should know about before consenting in a telehealth visit?
Across the integrated clinical program of approximately 3,500 subjects, the most common adverse events at the 1.75 mg dose were nausea (40.0%), flushing (20.3%), headache (11.3%), and injection-site reactions (13.2%) [03]. Nausea accounted for roughly 8% of discontinuations [03]. An ambulatory blood-pressure monitoring study in 397 women showed small, transient post-dose systolic BP increases of 2.4–3.2 mmHg, peaking within 4 hours and resolving within 12 [05]. Focal hyperpigmentation of the face, gums, or breasts was reported in approximately 1% of trial participants, with risk increasing for darker skin types and frequent dosing and possible incomplete resolution after discontinuation [08]. Bremelanotide is contraindicated in uncontrolled hypertension and known cardiovascular disease [06][12], and is not recommended in patients taking oral naltrexone for alcohol or opioid use disorder, because of a clinically important drug interaction [07].
Does insurance cover telehealth bremelanotide?
Coverage varies. Some payers limit telehealth coverage for women's sexual-health visits, and some exclude bremelanotide from formulary coverage, which can leave the patient with out-of-pocket cost for either the visit, the prescription, or both. The 2025 multi-country survey by the International Sexual Health and Reproductive Health Consortium documented uneven access and affordability for sexual and reproductive telehealth services across high-income countries [17]. Patients should confirm specifics with their plan and the platform before the visit.
Does the platform sell bremelanotide directly?
Legitimate telehealth operations don't sell the drug; they connect the patient to a state-licensed clinician who, after evaluation, may write a prescription that is filled by a separately licensed dispensing pharmacy. The drug is sold by the pharmacy, not the platform. A site that advertises 'PT-141 for sale' without a prescribing clinician, a video visit, and a licensed pharmacy in the loop is operating outside the standard-of-care framework documented in the sexual-medicine and ACOG telehealth literature [15][18][19].